Health Care and Biotech
Alcidion’s IT Targets Hospital Efficiency
Alcidion is an emerging operator in the field of hospital IT, with technology that can reduce deaths attributable to medical error. The stock price has doubled since it listed on ASX in February this year.
Dec 19 2016
Estia Health Beset By Uncertainty
Estia Health is beset by uncertainty surrounding the sustainability of earnings and this is not expected to moderate in the near term.
Dec 13 2016
Rebound For Sirtex
Michael Gable of Fairmont Equities suggests technically, Sirtex Medical should be set to recover.
Dec 13 2016
Sirtex Reaction Overdone
Increased competition has wedged dose sales for Sirtex Medical but brokers suspect the market’s reaction is overdone.
Dec 12 2016
Previous Stories
Prima Biomed Clinical Trials Offer Significant Upside
May 23 2011
Prima Biomed is moving to late stage clinical trials for its CVac cancer vaccine and Southern Cross sees significant upside potential.
Brain Resource Offers Profits And Potential
May 20 2011
Southern Cross Equities rates Brain Resource a Speculative Buy given potential upside as the company develops offering in the mental health and brain training markets.
Blood On The Floor
May 19 2011
The great plasma boom is over, Macquarie declares. CSL is a strong performer but growth will now be subdued for some time.
The Budget And The Stock Market
May 11 2011
There were no measures to either positively or negatively shock any particular stock market sector, but nor was there much burden removed from RBA monetary policy in last night’s Budget.
Phosphagenics: A Re-Rating In Progress?
May 06 2011
Phosphagenics is developing drug patch delivery technology and Southern Cross sees significant upside potential.
AUD Clouds Outlook For ResMed
May 02 2011
ResMed’s March quarter result has revealed revenue and margin pressures stemming from a strong Australian dollar.
Southern Cross Upgrades QRxPharma
Apr 20 2011
With QRxPharma close to filing for FDA approval for its MoxDuo compound, Southern Cross has upgraded to Buy.
Circadian Continues Offering Substantial Upside Potential
Apr 11 2011
Morningstar has ceased coverage on biotech Circadian Technologies, but the broker notes the upside potential story remains intact.
Valuation The Issue For Ramsay Health Care
Apr 06 2011
Ramsay Health Care announced the purchase of a hospital in France and a successful tender for another hospital in Queensland but the good news is tempered by a full valuation, say stockbrokers.
Biotron A Potential Re-Rating Story
Mar 29 2011
Southern Cross Equities expects favourable clinical trial results from anti-viral drug developer Biotron.
Analyse The Market From A Different Angle
Latest News
| 1 |
Today’s Financial Calendar – 08-07-20258:15 AM - Daily Market Reports |
| 2 |
ASX Winners And Losers Of Today – 07-07-25Jul 07 2025 - Daily Market Reports |
| 3 |
Australian Broker Call *Extra* Edition – Jul 07, 2025Jul 07 2025 - Daily Market Reports |
| 4 |
Investing In AI & Growth; A Personal ExperienceJul 07 2025 - International |
| 5 |
Australian Listed Real Estate Tables – 07-07-2025Jul 07 2025 - Weekly Reports |